First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer
Sponsor: Accent Therapeutics
This PHASE1 trial investigates Advanced Solid Tumors and Breast Cancer Recurrent and is currently actively recruiting participants. Accent Therapeutics leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Jul 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Accent Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .